Business Wire

BLUEHOLE-NEW-CONSUMPTION

3.12.2021 04:06:09 CET | Business Wire | Press release

Share
Bluehole Publishes a Feature Story on China’s Recent Vaping Regulations

China’s leading vaping media, Bluehole New Consumption, today published a feature story on recent vaping regulation updates in China.

Here below is the full article in English:

On December 2, 2021, China’s State Tobacco Monopoly Administration issued the draft rules governing e-cigarettes while the regulator has just released the exposure draft of national standards of e-cigarettes on November 30, 2021. Previously, China announced to bring e-cigarettes under tobacco monopoly law on November 26, hence the legal status of e-cigarettes.

The recent regulation updates have eliminated the uncertainties about the future of Chinese vaping industry, paving the way for the industry’s sustainable development.

According to iiMedia Research Group, the size of Chinese’ e-cigarette market has grown from RMB 550 million (USD 86 million) in 2013 to RMB 8.38 billion (USD 1.31 billion) in 2020, witnessing an eight-year compound annual growth rate of 72.5%.

World Health Organization estimates that China has over 300 million smokers, nearly one-third of the world's total. More than half of adult Chinese men are current tobacco smokers. By contrast, the e-cigarette penetration rate among Chinese smokers is less than 1%, indicating the massive development potential of Chinese e-cigarette market.

The legal recognition sends a positive signal that vaping could continue to serve as a harm reduction tool to help over 300 million Chinese smokers, significantly improving the country’s public health.

Moreover, the latest draft rules require vaping manufacturers to obtain a vaping production license, setting a high bar for vaping manufacturing in term of fund, facility, equipment and technology. Only the qualified manufacturers could be engaged in the production of e-cigarettes.

Released on November 30, the exposure draft of national standards of e-cigarettes covers a wide range of requirements, involving devices, materials, nicotine and additives. More importantly, the exposure draft requires all vaping devices to incorporate designs preventing children from misusing for the first time.

According to the exposure draft, the forthcoming national standards set specific quality requirements for vaping products, demanding manufacturers to improve product safety. It is expected that only the responsible industry players with quality assurance can comply with the standards. In the long run, the standards will foster sustainable development of the industry and provide consumers with more reliable products.

In terms of market landscape, it will eventually accelerate the market concentration and benefit market leaders with comprehensive safety management. Taking SMOORE for example, its safety standards have covered all PMTA tests and 134 in-house tests. It is the only company in China that has the capabilities of PMTA non-clinical testing and PMTA health risk assessment.

In a global context, public health regulators always tend to trust and approve products made by market leaders with technological edge for reliability backed by scientific evidence. For instance, in the US, British America Tobacco and Altria are the only two companies whose products have been granted premarket tobacco application (PMTA) approval by the Food and Drug Administration (FDA). China’s State Tobacco Monopoly Administration also requires all e-cigarettes sold in China to be registered and vaping companies to submit scientific evidence on product safety.

However, the new draft rules have little impact on exported e-cigarettes, as long as they comply with the laws, regulations and standards of destination countries. Therefore, it is relatively favorable to the vaping companies whose overseas markets account for the majority of revenue.

As the vaping manufacturing capital of the world, Shenzhen accounts for around 90% of the global vaping market share. The national mandatory standards and the draft rules are going to significantly change the vaping manufacturing in Shenzhen. Local manufacturers will transform from cost-oriented to technology-oriented. SMOORE, the world’s largest vaping manufacturer, is also ready to launch the next generation of FEELM atomization technology in December.

To read the original article, please visit: https://www.bluehole.com.cn/news/detail/47806

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release

Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh

Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release

- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur

Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release

Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i

Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release

Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up

Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye